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Abstract
Objective: We aimed to perform a systematic review and meta-analysis examining the impact of TB treatment at the
time of combination antiretroviral therapy (cART) initiation on subsequent mortality.
Methods: We searched PubMed, EMBASE, and selected conference proceedings for studies that report adult
mortality on cART, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-regression
analyses were used to examine the influence of study and population characteristics.
Results: 22 eligible cohort studies reported data on 98,350 (range 74-15,225) adults, of whom 14,779 (15%) were
receiving TB treatment at cART initiation. Studies of those receiving vs. not receiving TB treatment had an average
mortality relative risk of 1.10 (95% confidence interval 0.87-1.40) at 1-3 months (based upon 8 estimates), 1.15
(0.94-1.41) at 6-12 months (11 estimates), and 1.33 (1.02-1.75) at 18-98 months (10 estimates) following cART
initiation. However, there was a wide range of estimates and those at later time points were markedly heterogeneous.
Meta-regression identified factors associated with elevated average risk estimates: lower median baseline CD4
counts and adjustment for baseline hemoglobin at 1-3 months; longer length of follow-up and women-only studies at
6-12 months; and not adjusting for BMI/weight at 18-98 months.
Conclusions: Patients receiving TB treatment at cART initiation did not have a statistically significant estimated
increase in short-term risk of all-cause mortality as compared to those not receiving TB treatment. TB treatment was
significantly associated with increased mortality after about a year of cART, suggesting that patients with concurrent
TB treatment at cART initiation may benefit from continued support after TB treatment completion.
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Introduction
Tuberculosis (TB) continues to threaten the health of people
living with HIV (PLWH). Globally in 2011, 13% of incident TB
cases were co-infected with HIV and an estimated 0.4 million
TB deaths occurred among PLWH [1]. Access to combination
antiretroviral therapy (cART) has dramatically increased
survival, but a substantial number of PLWH die during the first
year of cART. The majority of deaths occur within the first three
months [2-5]. Autopsy studies have consistently shown TB to
be an important cause of death in PLWH, both in the pre-cART
[6-8] and cART eras [9].
In 2010, a meta-analysis of the effect of TB on mortality
found PLWH also suffering from TB had a greater risk of
mortality than TB-free individuals (hazard ratio [HR]: 1.8, 95%
confidence interval [CI]: 1.4-2.3) [10]. Due to the paucity of
studies reporting on patients on cART, the authors concluded
that the effect of TB on mortality in PLWH exposed to cART
must be further evaluated once more cohort study results
become available.
Given the World Health Organization’s 2010
recommendation that all PLWH with TB be initiated on cART,
regardless of CD4 count [11], and the goal of 100% cART
coverage of co-infected patients by 2015 [12], many individuals
will be initiating cART while concurrently on treatment for
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confirmed or clinically suspected active TB. PLWH who are
also being treated for TB may experience a differential
response to cART due to drug-drug interactions [13,14], an
increased risk of drug toxicity [13,14], immune reconstitution
inflammatory syndrome [15], and the potential for lower
adherence due to the high pill burden [14]. The effect of TB
treatment and its associated potential challenges and
complications on a patient’s response to cART is not yet clear
[16].
We aim to describe the impact of receiving TB treatment at
the time of cART initiation on subsequent mortality among HIV-
infected adults. We performed separate analyses to identify the
effect at 1-3 months, 6-12 months, and 18-98 months.
Methods
Search strategy and selection criteria
To investigate the effect of TB treatment at the time of cART
initiation on mortality, we carried out a systematic and sensitive
search using an a priori protocol developed according to
PRISMA guidelines [17] (Checklist S1). We searched PubMed
and EMBASE, as well as abstract databases from the 2009 to
2012 Conferences on Retroviruses and Opportunistic
Infections, International Union Against Tuberculosis and Lung
Disease World Conferences on Lung Health, and International
AIDS Society conferences. The search terms “HIV AND
Tuberculosis AND (Viral Load OR CD4 lymphocyte count OR
Mortality) AND Antiretroviral therapy” were used to identify
relevant articles in PubMed and EMBASE. Searches were
performed on March 1, 2013 and included original human
subjects cohort studies published since 1997 (the start of the
cART era). Additional articles were identified from reference
lists, reviews, and Web of Science citation lists.
H.M.S. and A.V.R. independently reviewed titles and
abstracts of original studies retrieved by the search. H.M.S.
reviewed full-text and references of selected articles. H.M.S.
and M.R.P. independently abstracted study data from full
reports; discrepancies were resolved by consensus or
consultation with A.V.R. and C.P.
Studies were included if they included both antiretroviral-
naïve HIV-infected individuals receiving and not receiving TB
treatment at cART initiation, and reported mortality after cART
initiation stratified by TB treatment status at cART initiation.
cART was defined as a treatment regimen containing three or
more antiretrovirals. Though we sought reports of cART-naïve
patients, studies with ≤10% antiretroviral-experienced patients
or patients only previously exposed to a single intrapartum
dose of nevirapine were also included. Studies of children <14
years of age were excluded. No additional exclusion criteria or
language restrictions were imposed.
Data extraction
The following information, if available, was abstracted from
each article: first author surname; publication year; study
design; study dates; length of follow-up; geographic location;
clinical setting; sample size; number receiving and not
receiving TB treatment; if TB treatment was the main exposure
of interest; types of TB included; culture confirmation of TB
cases; TB site; timing of TB treatment in relation to cART
initiation; percentage male; mean or median participant age;
proportion treatment-naïve; cART regimen; baseline median
CD4 count and HIV-RNA; measure of effect or event counts;
covariate adjustment; proportion lost-to-follow-up; and if
mortality was confirmed using a national death registry.
Statistical analysis
Reported mortality effect-measure estimates over any length
of time were abstracted. If only survival proportions among
those receiving or not receiving TB treatment were reported, a
risk ratio (RR) and 95% CI were calculated, as the RR
approximates the HR for an uncommon outcome. If an effect-
measure estimate was reported for those not receiving vs.
receiving TB treatment, the inverse of the reported effect-
measure estimate and CI were included. If only a p-value from
a univariate logistic regression model was presented, the 2x2
table was reconstructed and a RR was calculated. Standard
error estimates were inferred from reported CIs by [ln(upper
limit) - ln(lower limit)]/3.92 [18].
As tuberculosis is successfully treated in most patients after
six months of treatment, and the hazard of mortality following
cART initiation is not constant, we grouped available
cumulative effect estimates according to length of follow-up:
1-3 months, 6-12 months, and 18-98 months. None of the
eligible studies reported estimates at 4-5 months or 13-17
months following cART initiation. If a study reported multiple
estimates within a time category, the time frame closest to the
category midpoint was included in the primary analysis and
other time estimates were examined in sensitivity analyses.
The method of moments estimate of the among-populations
variance (τ2) and random-effects summarization using
unconditional variances were used to combine relative risks in
the three groups [19]. The p-values for a standard chi-square
homogeneity test statistic were used to assess overall
consistency among the effect estimates. τ2 was used to
calculate 95% population effects intervals [20] (where 95% of
populations are estimated to have their relative risks), opposite
effects proportions [21] (proportion of populations estimated to
experience a relative risk on the opposite side of the estimated
mean, in this case below unity), and 95% prediction intervals
[21] (95% of these intervals will cover the true value estimated
by a future study). Stratified and random-effects meta-
regression analyses were used to calculate stratum-specific
summary measures and 95% CIs, along with ratios of the
average RRs as described by Thompson and Sharp [22]. Study
characteristics with at least two studies per stratum were
eligible for inclusion in the meta-regression.
Funnel plots of ln(mortality relative risk) vs. the inverse-
variance weight of studies for each time category were visually
examined for asymmetry and statistically assessed using
methods proposed by Begg [23] and Egger [24] and the trim-
and-fill method of Duval and Tweedie [25]. STATA (version 12,
Stata corporation, College Station, TX) was used for these
analyses.
TB Treatment and cART Mortality
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Results
Selected studies
997 unique abstracts were reviewed: 824 from PubMed, 121
additionally from EMBASE, and 52 from conference
proceedings (Figure 1). Of these, 119 full-text articles were
selected for review. In total, 20 articles [2,26-44] and three
conference abstracts [45-47] were eligible. Four additional
articles met our inclusion criteria: two from reference lists
[48,49] and two from Web of Science citation searches [50,51].
One included abstract [46] was subsequently published as a
full article [52]; only data from the full article was included. Five
eligible studies were excluded: one [43] because a 2012 paper
[29] provided an updated estimate; four because they included
some early incident TB cases in their TB treatment-exposed
group [28,38,39,42].
Study and population characteristics
The 22 final studies provided data on 98,350 PLWH, of
which 14,779 (15%) were receiving TB treatment at cART
initiation. Selected study and population characteristics are
displayed in Table 1. All were cohort studies. Most publications
assessed mortality after cART initiation, regardless of regimen
type, though some reported estimates specific to nevirapine-
[31,41,48,49] or efavirenz-based [26,31,37] therapy. See Table
S1 for cART regimens used by each study. All studies used
cART initiation as the time origin, except one which began at
the commencement of cART education and adherence
sessions, with most patients starting cART a month or two later
[52]. Four studies included women previously exposed to a
single intrapartum dose of nevirapine [30-33], and two studies
included 3% [29] and 6% [36] antiretroviral-experienced
patients.
Ten studies examined TB treatment at cART initiation as the
main exposure of interest [26,29,31,35,37,41,47,49,51,52]. The
Figure 1.  Identification and selection of eligible
studies.  
doi: 10.1371/journal.pone.0078073.g001
other twelve studies examined TB treatment as a secondary
exposure; five examined any predictors of mortality
[27,33,34,44,48], three aimed to describe general cART
outcomes [2,30,32], and one each examined the primary
exposures of integrated vs. vertical HIV programs [36], positive
serum cryptococcal antigen [40], age [50], and hepatitis B and
C co-infections [45]. The type of TB being treated varied across
studies (Table S2). Only two studies had a substantial subset
of bacteriologically-confirmed TB cases [51,52] while others
included both confirmed and probable TB cases. Most articles
included any TB being treated at the time of cART initiation,
whereas others used a specific time period such as new TB
diagnosis at study entry [26,38] or diagnosis ≥1 month prior to
enrollment [41]. Nine studies reported detail on the duration of
TB treatment at the time of cART initiation (Table S3). One
study focused solely on pulmonary TB [29], and one censored
patients in the reference group that developed incident TB [31].
Mortality was mainly assessed using medical records and/or
confirmation from family or health workers, however two
studies additionally used national death registries [29,32]. In an
effort to quantify late mortality, two studies excluded deaths
occurring in the first three months [32,50]. Overall loss-to-
follow-up was reported by 19 studies and ranged from 0% to
21% (median 9%).
Two studies were limited to women only [30,33]. Mean
patient age ranged from 28 to 40 years (median 35 years), with
the youngest included age being 14 years [31]. One study
stratified mortality estimates according to age [50]. Median
baseline HIV-RNA ranged from 4.4 to 5.7 log10 copies/mL
(median 5.1), and baseline CD4 count ranged from 31 to 196
cells/μL (median 111). See Table S4 for baseline CD4 count
stratified by TB treatment status from each study, if available.
Relative risk of mortality
Thirty-one cumulative mortality relative risks were reported or
calculated among those receiving vs. not receiving TB
treatment at cART initiation (Figure 2). Most were HRs, though
eight RRs [26,30,37,41,47,49,52], four odds ratios
[27,40,44,48], and one incidence rate ratio [51] were also
included. Among the 21 adjusted estimates, 20 adjusted for
baseline CD4 count, 19 for gender, 18 for age, 13 for BMI or
weight, eight for hemoglobin, and two for adherence (defined
as timeliness of pharmacy attendance). Including only the
estimate corresponding to the longest follow-up time from each
study, the summarized relative risk of mortality in those
receiving vs. not receiving TB treatment across all time periods
was 1.24 (95% CI 1.05-1.46, τ2 = 0.097).
Eight relative risks of mortality by 1-3 months were reported,
without evidence of substantial heterogeneity (homogeneity p-
value = 0.11, Table 2). The random-effects summary estimate
was 1.10 (95% CI 0.87-1.40, τ2 = 0.045). The eleven mortality
relative risks by 6-12 months produced a random-effects
summary estimate of 1.15 (95% CI 0.94-1.41, τ2 = 0.041). By
18-98 months, the summarized relative risk indicated increased
mortality among patients receiving TB treatment (random
effects relative risk [RRRE] = 1.33, 95% CI 1.02-1.75, τ2 =
0.134), based upon 10 estimates. There was evidence of
TB Treatment and cART Mortality
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considerable heterogeneity for the 6-12 and 18-98 month
estimates (homogeneity p-values 0.06 and <0.01, respectively).
Meta-regression
Meta-regression results are displayed in Table S5. For 1-3
month mortality, lower median baseline CD4 counts and
adjustment for baseline hemoglobin appear to produce
somewhat higher relative risks. Among the 6-12 month
estimates, length of follow-up appeared to have the most
influence and produced the most homogenous strata,
suggesting that this 6-month window may be too wide. At 6 to 9
months following cART initiation, those receiving vs. not
receiving TB treatment had a RRRE of 0.93 (95% CI 0.68-1.28,
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homogeneity p-value = 0.14), whereas at 11 to 12 months the
RRRE was 1.29 (95% CI 1.06-1.56, homogeneity p-value =
0.61), indicating an increased risk of mortality after completion
of TB treatment. Studies limited to women only also reported
higher RRs (RRRE = 2.57, 95% CI 0.83-7.98). Among 18-98
month estimates, a longer follow-up time does not appear to
influence the results. However, adjustment for BMI or weight
tended to move the relative risk toward the null (RRRE = 1.01,
95% CI 0.84-1.21).
Funnel plot analysis
For 1-3 month estimates, the funnel plot gives the visual
appearance of a slight skew to the left (Document S1), but both
tests for asymmetry yielded p-values of 0.8, and only one
hypothetical missing result was imputed on the right by trim-
and-fill analysis, with little influence on the summary results. In
contrast, funnel plots for 6-12 and 18-98 months were skewed
more noticeably to the right and the tests for asymmetry
yielded lower p-values (Begg p = 0.2, Egger p = 0.03 for 6-12
months, Begg p = 0.3 and Egger p = 0.4 for 18-98 months).
Trim-and-fill imputed four hypothetically missing results at 6-12
months and two at 18-98 months, all on the left. The imputation
shifted the estimate of the random-effects average RR from
1.15 to 1.02 at 6-12 months and from 1.33 to 1.14 at 18-98
months.
Sensitivity analyses
As Makombe et al. (2007) [49] contained multiple estimates
of mortality in the 6-12 month time frame, only the six-month
estimate was included in primary analyses. The analysis was
then repeated, substituting in the 12-month estimate. As this
alternative estimate was similar in point estimate and precision
to the 6-month estimate, the substitution did not affect the
results or our conclusions. Likewise, Westreich et al. (2012)
[29] reported estimates at 36 months and 54 months.
Regardless of which was included, the analysis results did not
substantially differ. Additionally, as some studies reported
asymmetrical confidence intervals, a sensitivity analyses
assessed their impact on the summary measures (Document
S2).
Discussion
This systematic review and meta-analysis of studies
reporting the effect of TB treatment at cART initiation on
subsequent mortality among PLWH initiating therapy found that
TB treatment did not significant affect mortality on cART in the
short-term, but was associated with increased mortality after
about a year of cART. These results are important given the
many concerns about co-treatment including drug-drug
interactions, overlapping drug toxicities, immune reconstitution
inflammatory syndrome, and high pill burden. Our findings were
not sensitive to geographical study location (Africa vs. Asia or
Europe).
Overall, the summary estimates for early mortality were
lower than estimates for later mortality. This finding may be
Figure 2.  Forest plot of mortality relative risks reported by
22 studies.  The relative risks correspond to the estimated
effect of receiving vs. not receiving TB treatment at the time of
cART initiation on subsequent mortality among HIV-infected
adults. Estimates are ordered according to length of follow-up
time. Estimates were abstracted according to the precision
used by the original authors; estimates calculated using
available data are reported to 2 decimal places. Abbreviations:
cART, combination antiretroviral therapy; CI, confidence




Abbreviations: cART, combination antiretroviral therapy; EFV, Efavirenz-based cART; HIV, human immunodeficiency virus; NS, not specified; NVP, Nevirapine-based cART;
P, prospective study; R, retrospective study; TB, tuberculosis.
a. See Table S1 for detailed information on cART regimens from each study, if available
b. See Table S4 for baseline CD4 cell count stratified by TB treatment status from each study, if available
c. If a study reported relative risks for multiple time periods, an overall mortality estimate is indicated for each respective time period
d. (a) Nevirapine-based cART; (b) Efavirenz-based cART
e. For these studies, the letters after the author’s name refer to the estimates reported at differing time points. For example, Makombe (a) refers to the 6-month estimate and
Makombe (b) refers to the 12-month estimate.
f. (a,b) patients <50 years old; (c,d) patients ≥50 years old
doi: 10.1371/journal.pone.0078073.t001
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contrary to expectations, but could be due to several factors.
First, patients on concurrent TB therapy at cART initiation may
experience a lower short-term risk of all-cause mortality
because TB medications are also effective against infectious
diseases other than TB [53]. Second, most PLWH receiving TB
treatment often receive co-trimoxazole preventive therapy,
which further reduces the risk of death from non-TB infectious
diseases. Third, prior to cART initiation, PLWH on TB treatment
may have been engaged in care for longer than other PLWH.
Fourth, TB deaths can occur early during TB treatment, i.e.,
prior to the initiation of cART, creating possible left-censoring.
However, PLWH not diagnosed with TB also may die prior to
cART initiation, and studies did not provide enough information
to determine if left-censoring was differential between the two
groups. Fifth, undiagnosed and untreated TB among the
comparison group may have biased estimates of early mortality
toward the null. Autopsy studies consistently show that
undiagnosed TB continues to be a major cause of death
among HIV-infected adults [6-8], even in the cART era [9].
This meta-analysis has a number of limitations. Since being
treated for active TB is not an exposure suitable for a
randomized controlled trial, all studies included in our meta-
analysis were observational and subject to biases. First, the
outcome of mortality may have been misclassified in people
lost-to-follow-up. Rates of follow-up loss were variable in the
included studies, ranging from 0% to 21%. cART programs with
high losses of patients and incomplete death ascertainment
can seriously underestimate mortality, with 12% to 87% of
patients loss-to-follow-up in fact being deceased [54].
Misclassification of deaths would only produce bias in the
estimated relative risks if this misclassification was differential
between compared groups [55] or dependent on errors in
measuring other variables. This is especially relevant for
mortality estimates during the first six months of cART, when
loss-to-follow-up may be differential due to regular follow-up for
TB treatment. We attempted to examine if mortality
confirmation by national death registry affected mortality effect
estimates. This was only possible for two studies, both with
18-98 months of follow-up.
Table 2. Meta-analysis results for the effect of TB treatment
on mortality, by length of follow-up time.
Length of follow-up time 1-3 months 6-12 months 18-98 months
No. of studies 8 11 10











95% population effects interval (0.73, 1.67) (0.77, 1.71) (0.65, 2.73)
Opposite effects proportion 32.2% 24.8% 21.6%
95% prediction interval (0.62, 1.97) (0.69, 1.91) (0.55, 3.23)
Abbreviations: CI, confidence interval; RRRE, random-effects summary relative
risk; TB, tuberculosisRR: risk ratio
doi: 10.1371/journal.pone.0078073.t002
Second, the exposure, prevalent TB treatment at cART
initiation, captures both confirmed active TB disease and
exposure to anti-tuberculosis drugs for clinically suspected TB.
This combined exposure is useful from a health systems
perspective, particularly in low-resource countries, where active
TB cannot always be confirmed, especially in PLWH. The
included studies used a variety of methods for determining who
had active TB and should receive treatment, and no studies
were exclusively limited to bacteriologically-confirmed TB
cases. Consequently, active TB could have been misclassified
and some patients included in this meta-analysis may have
received TB treatment even though they did not have TB. In
addition, some patients with active TB may not have been
diagnosed.
Third, there was much heterogeneity in the duration of TB
treatment prior to cART initiation, with some patients on TB
therapy for six months and others beginning TB treatment and
cART concurrently. While the timing of TB treatment in relation
to cART initiation is an important variable to consider when
evaluating mortality [43,56-59], the included studies did not
provide enough information on duration of TB treatment to
systematically evaluate its effect on our results. Future studies
should describe the duration of TB treatment in more detail to
facilitate meta-analysis, though a pooled patient-level analysis
or randomized controlled trial are study designs better suited to
assess this.
Some degree of funnel plot asymmetry was apparent for
each time period, possibly due to publication bias or other
factors. A direct effect measure was not available from each
study, and published estimation methods [18] were used to
calculate the effect measure for five studies. These estimation
techniques involve a number of assumptions and may have
introduced bias or affected variance estimates. Additionally, in
12 of 22 studies, TB treatment was not the primary exposure
and covariates included in multivariate models may differ from
ideal confounder adjustment for this research question. Some
studies only included TB treatment in their multivariable model
for mortality because it was a statistically significant predictor,
which may explain some funnel plot asymmetry.
It was difficult to examine the influence of study or population
characteristics on the effect estimates, as grouping studies by
specific characteristics produced small strata with imprecise
estimates. Furthermore, some characteristics are correlated.
For example, risk ratios and odds ratios tended to be higher
than hazard ratios, but the former also tended to be unadjusted
estimates. Also, as studies adjusted for sets of key covariates,
it was difficult or impossible to separate out the influence of
adjusting for a specific covariate (see footnotes of Table S5).
Given the patient characteristics of the included studies, the
results are most generalizable to therapy-naïve adults in Sub-
Saharan Africa with relatively low CD4 counts at cART
initiation. More studies in populations outside of sub-Saharan
Africa, particularly in North America, would be useful additions
to the literature. This review only includes studies among
adults; it is unknown whether the relationship holds in children.
Similarly, it is possible that cART regimen would modify the
effect of TB treatment due to drug-drug interactions, and
TB Treatment and cART Mortality
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regimen-specific estimates would be of most use to clinicians
treating co-infected patients.
In conclusion, our results reinforce the concept [29] that TB
treatment does not increase early mortality after cART initiation
— the issue is undiagnosed and untreated TB — underscoring
the need for intensified case finding to reduce early mortality
associated with undiagnosed TB in PLWH. After about a year
of cART, TB treatment was associated with increased mortality,
despite the possibility of downward biases. This association
should be elucidated in future studies, with an emphasis on
separating possible effects of TB treatment from effects of
active TB itself. In the meantime, patients receiving concurrent
TB treatment at cART initiation may benefit from continued
support after TB treatment completion.
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